Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
SAN DIEGO, Feb. 20, 2018 -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, enhances its existing platform for chimeric antigen receptor (CAR) T-cell agent evaluation with bioluminescent imaging capabilities.
CAR T-cell therapies are an exciting advent in the evolving field of immune-therapeutics. CAR T-cell agents utilize CAR T-cells that recognize tumor-associated antigens and subsequently promote tumor elimination. The remarkable efficacy of CAR T-cell compounds has led to hundreds of clinical trials with two notable successes recently approved by the FDA to treat refractory B-cell precursor acute lymphoblastic leukemia (ALL).
CrownBio, a leader in the field of preclinical immuno-oncology research, offers a CAR T-cell platform for proof-of-concept and therapeutic efficacy validation. Clinically relevant in vivo and in vitro models combine with a comprehensive suite of analytical services to enable efficient, early evaluation of CAR T-cell agents. The addition of bioluminescence imaging (BLI) for non-invasive evaluation of systemic and orthotopic tumor progression, in real-time, further enhances an already robust platform and provides a unique set of solutions to advance CAR T-cell therapies.
“We are committed to delivering innovative services to help our clients’ develop improved cancer therapeutics,” said Dr. Rajendra Kumari, CrownBio’s Chief Scientific Officer, UK. “Our non-invasive BLI capabilities, applied to CAR T-cell evaluation platform, deliver cutting-edge in vivo data that helps drug developers uncover insights to guide successful downstream development and clinical application of CAR T-cell agents.”
Learn more about CrownBio’s CAR T-cell evaluation platform at https://www.crownbio.com/oncology/immuno-oncology/car-t-cell-therapy-models/
About Crown Bioscience Inc.
CrownBio is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, CrownBio enables clients to deliver superior clinical candidates.
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc.
[email protected]
